Director WIERENGA WENDELL sold 20,000 shares of CYTK at $66.14 on 2025-12-22, reducing holdings 38.1% to 32,444 shares.
WIERENGA WENDELL, a Director, executed a substantial sale of 20,000 shares at $66.14, representing a 38.1% reduction in his holdings at a price $2.85 above the current market price of $63.29. The sale is notable given the company's recent strong 90-day performance (+31.1%) and explosive revenue growth (FY vs prior FY: +145.3%), yet Cytokinetics remains unprofitable with a net income of $-306,178,000.00 over its most recent full fiscal year. This directional contrast—selling during a growth and momentum phase while the company operates at substantial losses—merits investor attention to understand the insider's intent and assessment of near-term risk relative to the sustained operational losses.